MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Clinical transplants · 2014

Highly Sensitized Patients: Miami Transplant Institute Experience.

Mattiazzi Adela D, Centeno Alexandra, Amador Alexandra, Fernandez-Bango Casiana, Scowby Catherine Dillard, O'Rourke Marian, Hill-Matthie Tamieka, Patel Ronak, Barrios Frances, Ruiz Phillip, Chen Linda, Saghesima Junichiro, Ciancio Gaetano, Burke George W, Goldstein Michael, Chandar Jayanthi, Contreras Gabriel, Roth David, Kupin Warren, Guerra Giselle, Vianna Rodrigo

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Transplantation continues to be challenging in highly sensitized patients. Herein, we compared induction immunosuppression (IS) based on immunologic risk stratification and desensitization with intravenous immunoglobulin (IVIG).

METHODS

Of the 42 highly sensitized kidney and 3 kidney-pancreas transplant recipients who underwent IVIG for desensitization from 2008-2014, 10 (Control group) received standard induction IS with antithymocyte globulin, basiliximab, and methylprednisolone, and 35 (Rituximab group) received standard IS with rituximab ± IVIG ± plasmapheresis. Immunologic risk stratification was based on donor specific antibodies (DSA), flow crossmatch ratio, and calculated panel reactive antibody. All patients received tacrolimus, mycophenolate, and steroids for maintenance IS. Unacceptable antigen cut-offs for class I and II DSA were 6000 and 9000 mean fluorescence intensity and 2.0 and 4.4 channel shift ratios for T and B cell flow cytometry crossmatch, respectively. All complement dependent cytotoxicity T cell crossmatch negative patients were transplanted.

RESULTS

Characteristics between groups, including high risk level, previous transplantation rate, number of human leukocyte antigen mismatches, delayed graft function rate, rejection rate, serum creatinine, and estimated glomerular filtration rate at 1 year (1.48 ± 0.6 and 50 ± 17 versus 1.1 ± 0.4 mg/dl and 66 25 ml/min) were not statistically significant between the Control and the Rituximab groups, respectively. Waiting time for the Control group was 6.4 years versus 4.1 years for the Rituximab group (p = 0.009). The cumulative proportion of patients who remain free of death or allograft failure was significantly higher in the Rituximab (87%) versus the Control group (60%) (p = 0.047).

CONCLUSIONS

In highly sensitized patients who received desensitization with IVIG, the addition of Rituximab to our standard IS (and/or IVIG and plasmapheresis as per the immunologic risk stratification model) resulted in higher cumulative patient and graft survival.

Для цитирования: Mattiazzi Adela D, Centeno Alexandra, Amador Alexandra, Fernandez-Bango Casiana, Scowby Catherine Dillard, O'Rourke Marian, Hill-Matthie Tamieka, Patel Ronak, Barrios Frances, Ruiz Phillip, Chen Linda, Saghesima Junichiro, Ciancio Gaetano, Burke George W, Goldstein Michael, Chandar Jayanthi, Contreras Gabriel, Roth David, Kupin Warren, Guerra Giselle, Vianna Rodrigo. Highly Sensitized Patients: Miami Transplant Institute Experience.. Clinical transplants. 2014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.